Biomarker approaches in major depressive disorder evaluated in the context of current hypotheses

Biomarkers in Medicine

Volumn 9, Issue 3, 2015, Pages 277-297

  Jentsch, Mike C ^a   Van Buel, Erin M ^b   Bosker, Fokko J ^a,b   Gladkevich, Anatoliy V ^a   Klein, Hans C ^a,b   Oude Voshaar, Richard C ^a   Ruhé, Eric G ^a   Eisel, Uli L M ^b   Schoevers, Robert A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

biomarkers; clinical research; genomics; major depressive disorder; neuro imaging; preclinical research; proteomics

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; HYDROCORTISONE; MONOAMINE; NEUROTROPHIC FACTOR;

AUTOPSY; BLOOD ANALYSIS; CEREBROSPINAL FLUID LEVEL; EPIGENETICS; GENE EXPRESSION; GENETIC ASSOCIATION; HIPPOCAMPUS; HORMONE BLOOD LEVEL; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHESIS; IMMUNITY; INFLAMMATION; MAJOR DEPRESSION; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROIMAGING; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; PROTEOMICS; REVIEW; STRESS; URINALYSIS; ANIMAL; DEPRESSIVE DISORDER, MAJOR; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; BIOLOGICAL MARKERS; DEPRESSIVE DISORDER, MAJOR; HUMANS;

EID: 84923854454     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.14.114     Document Type: Review

References (220)

1. Bromet E, Andrade H, Hwang I et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 9, 90 (2011).
2. van Loo HM, de Jonge P, Romeijn JW, Kessler RC, Schoevers RA. Data-driven subtypes of major depressive disorder: a systematic review. BMC Med. 10, 156-168 (2012).
3. Belmaker RH, Agam G. Major depressive disorder. N. Engl. J. Med. 358(1), 55-68 (2008).
4. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 122, 509-522 (1965).
5. Ruhe HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol. Psychiatry 12, 331-359 (2007).
6. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23, 477-501 (2000).
7. Zunszain P, Anacker C, Cattaneo A, Carvalho L, Pariante C. Glucocorticoids, cytokines and brain abnormalities in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 722-729 (2011).
8. Gardner A, Boles RG. Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(3), 730-743 (2011).
9. Zhang H, Vutskits L, Pepper MS, Kiss JZ. VEGF is a chemoattractant for FGF-2-stimulated neural progenitors. J. Cell Biol. 163(6), 1375-1384 (2003).
10. Gaughran F, Payne J, Sedgwick PM, Cotter D, Berry M. Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. Brain Res. Bull. 70(3), 221-227 (2006).
11. Segi-Nishida E, Warner-Schmidt J, Duman RS. Electroconvulsive seizure and VEGF increase the proliferation of neural-stem-like cells in rat hippocampus. Proc. Natl Acad. Sci. USA 105, 11352-11357 (2008).
12. aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ 180(3), 305-313 (2009).
13. Vogelzangs N, Duivis HE, Beekman AT et al. Assoiciation of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl. Psychiatry 2, e79 (2012).
14. Lamers F, Vogelzangs N, Merikangas KR, de Jonge P, Beekman AT, Penninx BW. Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol. Psychiatry 18, 692-699 (2013).
15. Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J. Clin. Psychiatry 69(Suppl. E1), 4-7 (2008).
16. Doris A, Ebmeier K, Shajahan P. Depressive illness. Lancet 354, 1369-1375 (1999).
17. Asberg M, Bertilsson L, Martensson B, Scalia-Tomba GP, Thorén P, Traskman-Bendz, . CSF monoamine metabolites in melancholia. Acta Psychiatr. Scand. 69, 201-219 (1984).
18. Cheethman SC, Crompton MR, Czudek C, Horton RW, Katona CL, Reynolds GP. Serotonin concentrations and turnover in brains of dperessed suicides. Brain Res. 502, 322-340 (1989).
19. Pryor JC, Sulser F. Evolution of the monoamine hypothesis of depression. In: Biological Aspects of Affective Disorders. Horton RW, Katona CLE (Eds). Academic Press, NY, USA, 77-94 (1991).
20. Nemeroff CB, Knight DL, Franks J, Craighead WE, Krishnan, KRR. Further studies on platelet serotonin transporter binding in depression. Am. J. Psychiatr. 151, 1623-1625 (1994).
21. Arango V, Underwood MD, Mann JJ. Alterations in monoamine receptors in the brain of suicide victims. J. Clin. Psychopharmacol. 12, 8S-12S (1992).
22. Bakish D, Cavazzoni P, Chudzik J, Ravindran A, Hrdina PD. Effects of selective serotonin reuptate inhibitors on platelet serotonin parameters in major depressive disorder. Biol. Psychiatry 41, 184-190 (1997).
23. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J. Clin. Psychiatry (Suppl. 6), 4-6 (2000).
24. Delgado PL. Depression: the case for a monoamine deficiency. J. Clin. Psychiatry 61(Suppl. 6), 7-11 (2000).
25. Ehlert U, Gaab J, Heinrichs M. Psychoneuroendocrinological contributions to the etiology of depression, posttraumatic stress disorder, and stress-related bodily disorders: the role of the hypothalamus-pituitary-adrenal axis. Biol. Psychol. 57, 141-152 (2001).
26. Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol. Psychiatry 7, 254-275 (2002).
27. Merali Z, Du L, Hrdina P. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J. Neurosci. 24, 1478-1485 (2004).
28. MacMaster FP, Russell A, Mirza Y et al. Pituitary volume in treatment-naive pediatric major depressive disorder. Biol. Psychiatry 60, 862-866 (2006).
29. Steckler T, Holsboer F, Reul JM. Glucocorticoids and depression. Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 13(4), 597-614 (1999).
30. Ehlert U, Gaab J, Heinrichs M. Psychoneuroendocrinological contributions to the etiology of depression, posttraumatic stress disorder, and stress-related bodily disorders: the role of the hypothalamus-pituitary-adrenal axis. Biol. Psychol. 57, 141-152 (2001).
31. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. J. Am. Med. Assoc. 267, 1244-1252 (1992).
32. Thase EA. Biological aspects of depression. In: Handbood of Depression . Gotlib IH, Hammen CL (Eds). Guilford Press, UK (2002).
33. Stetler C, Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. Psychosom. Med. 73(2), 114-126 (2011).
34. Carroll BJ, Cassidy F, Naftolowitz D. Pathophysiology of hypercortisolism in depression. Acta Psychiatr. Scand. Suppl. 433, 90-103 (2007).
35. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry 19, 11-38 (1995a).
36. Maes M, Smith R, Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinol. 20, 111-116 (1995b).
37. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 65(9), 732-741 (2009).
38. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27(1), 24-31 (2006).
39. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 201-217 (2005).
40. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 9(1), 46-56 (2008).
41. Dantzer R. Cytokine, sickness behavior, and depression. Immunol. Allergy Clin. North Am. 29, 247-264 (2009).
42. Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 31(5), 1044-1053 (2007).
43. Vogelzangs N, Beekman AT, van Reedt Dortland AK et al. Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users. Neuropsychopharmacology 39(7), 1624-1634 (2014).
44. Duivis HE, Vogelzangs N, Kupper N, de Jonge P, Penninx BW. Association of somatic and cognitive symptoms of depression and anxiety with inflammation: findings from The Netherlands Study of Depression and Anxiety (NESDA). Psychoneuroendocrinology 38(9), 1573-1585 (2013).
45. Song C, Wang H. Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(3), 760-768 (2011).
46. Videbech P. MRI findings in patients with affective disorder: a meta-analysis. Acta Psych. Scand. 96, 157-168 (1997).
47. Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am. J. Psychiatry 161, 1957-1166 (2004).
48. MacQueen G, Frodl T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research. Mol. Psychiatry 16, 252-264 (2011).
49. Tanis KQ, Newton SS, Duman RS. Targeting neurotropic/growth factor expression and signaling for antidepressant drug development. CNS Neurol. Disord. Drug Targets 6, 151-160 (2007).
50. Brunoni AR, Lopes M, Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int. J. Neuropsychopharmacol. 11, 1169-1180 (2008).
51. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analysis and implications. Biol. Psychiatry 64, 527-532 (2008).
52. Bocchio-Chiavetto L, Bagnardi V, Zanardini R et al. Serum and plasma BDNF levels in major depression; a replication study and meta-analysis. World J. Biol. Psychiatry 11, 763-773 (2010).
53. Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (n=9484). Mol. Psychiatry 1-10 (2013).
54. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 15, 7539-7547 (1995).
55. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. 20, 9104-9110 (2000).
56. Bosker FJ, Hartman CA, Nolte IM et al. Poor replication of candidate genes for major depressive disorder using genome-wide association data. Mol. Psychiatry 16, 516-532 (2011).
57. Reid IC, Stewart CA. Brain plasticity and antidepressant treatments: new cells, new connections. Neurotox Res. 6(6), 483-489 (2004).
58. Stockmeier CA. Neurobiology of serotonin in depression and suicide. Ann. NY Acad. Sci. 836, 220-232 (1997).
59. Raedler TJ, Wiedemann K. CSF-studies in neuropsychiatric disorders. Neuro Endocrinol. Lett. 27, 297-305 (2006).
60. Xu HB, Zhang RF, Luo D et al. Comparative proteomic analysis of plasma from major depressive patients: identification of proteins associated with lipid metabolism and immunoregulation. Int. J. Neuropsychopharmacol. 15, 1413-1425 (2012).
61. Zheng P, Wang Y, Chen L et al. Identification and validation of urinary metabolite biomarkers for major depressive disorder. Mol. Cell Proteomics 12, 207-214 (2013).
62. Syvälahti EK. Biological aspects of depression. Acta Psychiatr. Scand. Suppl. 377, 11-15 (1994).
63. Willner P. Animal models of depression: validity and applications. Adv. Biochem. Psychopharmacol. 49, 19-41 (1995).
64. Willner P, Mitchell PJ. The validity of animals models of predisposition to depression. Behav. Pharmacol. 13, 169-188 (2002).
65. Knott V, Mahoney C, Kennedy S, Evans K. Pre-treatment EEG and it's relationship to depression severity and paroxetine treatment outcome. Pharmacopsychiatry 33(6), 201-205 (2000).
66. Liu WB, Yu HL, Jiang B et al. Correlation of neurochemical metabolism with memory function in young adult patients with first-episode depression studied with proton magnetic resonance spectroscopy. J. Zhejiang Univ. Med. Sci. 42, 450-455 (2013).
67. Rive MM, van Rooijen G, Veltman DJ, Phillips ML, Schene AH, Ruhé HG. Neural correlates of dysfunctional emotion regulation in major depressive disorder. A systematic review of neuroimaging studies. Neurosci. Biobehav. Rev. 37, 2529-2553 (2013).
68. Ruhé HG, Visser, AKD, Frokjaer V, Haarman, BCM, Klein HC, Booij J. Molecular imaging of depressive disorders. In: PET and SPECT in Psychiatry. Dierckx RAJO, Otte A, de Vries EFJ, van Waarde A, den Boer JA (Eds). Springer Verlag, 93-172 (2014).
69. Hoflich A, Baldinger P, Savli M, Lanzenberger R, Kasper S. Imaging treatment effects in depression. Rev. Neurosci. 23(3), 227-252 (2012).
70. Cohen-Woods S, Craig I, McGuffin P. The current state of play on the molecular genetics of depression. Psychiatr. Med. 43, 673-687 (2013).
71. Hepgul N, Cattaneo A, Zunszain PA, Pariante CM. Depression pathogenesis and treatment: what can we learn from blood mRNA expression? BMC Med. 11, 28-7015-7011-28 (2013).
72. Duman RS. Depression: A case of neuronal life and death? Biol. Psychiatry 56, 140-145 (2004).
73. Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci. 62(7), 583-606 (1998).
74. Goebel MU, Mills PJ, Irwin MR, Ziegler MG. Interleukin-6 and tumor necrosis factor-alpha production after acute psychological stress, exercise, and infused isoproterenol: differential effects and pathways. Psychosom. Med. 62(4), 591-598 (2000).
75. van West D, Maes M. Activation of the inflammatory response system: a new look at the etiopathogenesis of major depression. Neuro Endocrinol. Lett. 20, 11-17 (1999).
76. Leonard BE. The immune system, depression and the action of antidepressants. Prog. Neuropsychopharmacol. Biol. Psychiatry 25, 767-780 (2001).
77. Kohman RA, Rhodes JS. Neurogenesis, inflammation and behavior. Brain Behav. Immun. 27(1), 22-32 (2013).
78. Das S, Basu A. Inflammation: a new candidate in modulating adult neurogenesis. J. Neurosci. Res. 86(6), 1199-1208 (2008).
79. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(3), 702-721 (2011).
80. Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 379(9820), 1045-1055 (2012).
81. Hahn T, Marquand AF, Ehlis AC et al. Integrating neurobiological markers of depression. Arch. Gen. Psychiatry 68, 361-368 (2011).
82. Zunszain P, Anacker C, Cattaneo A, Carvalho L, Pariante C. Glucocorticoids, cytokines and brain abnormalities in depression. Progr. Neuropsychopharmacol. Biol. Psychiatry 35, 722-729 (2011).
83. Hasler G, Northoff G. Discovering imaging endophenotypes for major depression. Mol. Psychiatry 16, 604-619 (2011).
84. Papakostas GI, Shelton RC, Kinrys G et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol. Psychiatry 18, 332-339 (2013).
85. Pizzagalli D. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 36(1), 183-206 (2011).
86. Drevets WC, Price JS, Furey ML. Brain structural and functional abormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct. Funct. 213, 93-118 (2008b).
87. Drevets WC, Savitz J, Trimble M. The subgenual anterior cingulate cortex in mood disorders. CNS Spectr. 13, 663-681 (2008a).
88. Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception II: Implications for major psychiatric disorders. Biol. Psychiatry 54, 515-528 (2003).
89. Phillips ML, Ladouceur CD, Drevets WC. A neural model of voluntary and automatic emotion regulation: implications for understanding the pathophysiology and neurodevelopment of bipolar disorder. Mol. Psychiatry 13, 829; 833-857 (2008).
90. Marchetti I, Koster EH, Sonuga-Barke EJ, de Raedt R. The default mode network and recurrent depression: a neurobiological model of cognitive risk factors. Neuropsychol. Rev. 22(3), 229-251 (2012).
91. Craddock N, Owen MJ. The Kraepelinian dichotomy - going, going... but still not gone. Br. J. Psychiatry 196, 92-95 (2010).
92. Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am. J. Psychiatry 161, 1957-1966 (2004).
93. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 59, 1116-1127 (2006).
94. Hamilton JP, Gotlib IH. Neural substrates of increased memory sensitivity for negative stimuli in major depression. Biol. Psychiatry 63, 1155-1162 (2008).
95. Blank T, Prinz M. Microglia as modulators of cognition and neuropsychiatric disorders. Glia 61(1), 62-70 (2013).
96. Puchino N, Russo M, Santoro AN, Litta P, Cela V, Genazzani AR. Steroid hormones and BDNF. Neuroscience 239, 271-279 (2013).
97. Perlman SB, Almeida JR, Kronhaus DM et al. Amygdala activity and prefrontal cortex-amygdala effective connectivity to emerging emotional faces distinguish remitted and depressed mood states in bipolar disorder. Bipolar Disord. 14, 162-174 (2012).
98. Drevets WC, Price JS, Furey ML. Brain structural and functional abormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct. Funct. 213, 93-118 (2008b).
99. Groenewold NA, Opmeer EM, de Jonge P, Aleman A, Costafreda SG. Emotional valance modulates brain functional abnormalities in depression: evidence from a meta-analysis of fMRI studies. Neurosci. Biobehav. Rev. 37(2), 152-163 (2013).
100. Phillips ML, Drevets WC, Rauch SL, Lane R. Neurobiology of emotion perception II: implications for major psychiatric disorders. Biol. Psychiatry 54, 515-528 (2003).
101. Almeida JR, Versace A, Mechelli A et al. Abnormal amygdala-prefrontal effective connectivity to happy faces differentiates bipolar from major depression. Biol. Psychiatry 66, 451-459 (2009).
102. Almeida JR, Versace A, Hassel S, Kupfer DJ, Phillips ML. Elevated amygdala activity to sad facial expressions: a state marker of bipolar but not unipolar depression. Biol. Psychiatry 67, 414-421 (2010).
103. 11C]DASB. Am. J. Psychiatry 164, 1858-1865 (2007).
104. Meyer JH, Wilson AA, Sagrati S et al. Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch. Gen. Psychiatry 66, 1304-1312 (2009).
105. Hsieh PC, Lee IH, Yeh TL et al. Distribution volume ratio of serotonin and dopamine transporters in euthymic patients with a history of major depression - a dual-isotope SPECT study. Psychiatr. Res. 184, 157-161 (2010).
106. Rabiner EA, Bhagwagar Z, Gunn RN, Cowen PJ, Grasby PM. Preferential 5-HT1A autoreceptor occupancy by pindolol is attenuated in depressed patients: effect of treatment or an endophenotype of depression? Neuropsychopharmacology 29(9), 1688-1698 (2004).
107. 11C]DASB. Int. J. Neuropsychopharmacol. 13, 715-724 (2010).
108. 18)F]-fluoro-(2S)-exaprolol for imaging cerebral beta-adrenergic receptors with PET. Neurochem. Int. 53(5), 173-179 (2008).
109. Kraus C, Hahn A, Savli M et al. Serotonin-1A receptor binding is positively associated with gray matter volume: a multimodal neuroimaging study combining PET and structural MRI. Neuroimage 63(3), 1091-8 (2012).
110. 123l]beta-CIT SPECT in major depressive disorder versus controls: Effect of season and gender. Eur. J. Nucl. Med. Mol. Imaging 36(5), 841-849 (2009).
111. Meyer JH. Neuroimaging markers of cellular function in major depressive disorder: implications for therapeutics, personalized medicine, and prevention. Clin. Pharmacol. Ther. 91, 201-214 (2012).
112. Meyer JH. Neurochemical imaging and depressive behaviours. Curr. Top. Behav. Neurosci. 14, 101-134 (2013).
113. van Waarde A, Vaalburg W, Doze P, Bosker FJ, Elsinga PH. PET imaging of beta-adrenoreceptors in human brain: a realistic goal or a mirage? Curr. Pharm. Des. 10(13), 1519-1536 (2004).
114. Savitz JB, Drevets WC. Neuroreceptor imaging in depression. Neurobiol. Dis. 52, 49-65 (2013).
115. Shrestha S, Hirvonen J, Hines CS et al. Serotonin-1A receptors in major depression quantified using PET: controversies, confounds, and recommendations. Neuroimage 59, 3243-3251 (2012).
116. Smith DF, Jakobsen S. Molecular tools for assessing human depression by positron emission tomography. Eur. Neuropsychopharmacol. 19, 611-628 (2009).
117. Steiniger B, Kniess T, Bergmann R, Pietzsch J, Wuest FR. Radiolabeled glucocorticoids as molecular probes for imaging brain glucocorticoid receptors by means of positron emission tomography (PET). Mini Rev. Med. Chem. 8(7), 728-739 (2008).
118. Chauveau F, Piérard C, Corio M et al. Mediodorsal thalamic lesions block the stress-indued inversion of serial memory retrieval pattern in mice. Behav. Brain Res. 203(2), 270-278 (2009).
119. 11C]-(R)-PK11195 in a rat model of herpes encephalitis. Mol. Imaging Biol. 11(6), 386-398 (2009).
120. 11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease. Parkinsonism Relat. Disord. 16(1), 57-59 (2010).
121. 11)C]PK11195 in an acute rodent model. Eur. J. Nucl. Med. Mol. Imaging 37(5), 962-972 (2010).
122. Couillard-Despres S, Vreys R, Aigner L, Van der Linden A. In vivo monitoring of adult neurogenesis in health and disease. Front. Neurosci. 5, 67 (2011).
123. 11C]raclopride in the human brain. Synapse 16, 255-262 (1994).
124. Zald DH, Boileau I, El-Dearedy W et al. Dopamine transmission in the human striatum during monetary reward tasks. J. Neurosci. 24, 4105-4112 (2004).
125. 11C] raclopride displacement studies: understanding the true mechanism. Mol. Imaging Biol. 7, 45-52 (2005).
126. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 20, 423-451 (2000).
127. Veltman DJ, Ruhé HG, Booij J. Investigating serotonergic function using positron emission tomography: overview and recent findings. Curr. Pharm. Des. 16, 1979-1989 (2010).
128. Paterson LM, Kornum BR, Nutt DJ, Pike VW, Knudsen GM. 5-HT radioligands for human brain imaging with PET and SPECT. Med. Res. Rev. 33, 54-111 (2013).
129. Olbrich S, Arns M. EEG biomarkers in major depressive disorder: discriminative power and prediction of treatment response. Int. Rev. Psychiatry 25(5), 604-618 (2013).
130. Hosang G, Shiles C, Tansey K, McGuffin P, Uher R. Interaction between stress and the BDNF Val66Met polymorphism in depression: a systematic review and meta-analysis. BMC Med. 12, 7 (2014).
131. Gladkevich AV, Kauffman HF, Korf J. Lymphocytes as a neural probe: potential for studying psychiatric disorders. Biol. Psychiatry 28, 559-576 (2004).
132. López-León LS, Janssens AC, González-Zuloeta Ladd AM et al. Meta-analyses of genetic studies on major depressive disorder. Mol. Psychiatry 13, 772-785 (2008).
133. López-León LS, Croes EA, Sayed-Tabatabaei FA, Claes S, van Broeckhoven C, van Duijn CM. The dopamine D4 receptor gene 48-base-pair-repeat polymorphism and mood disorders: a meta-analysis. Biol. Psychiatry 57, 999-1003 (2005).
134. Chen K, Ridd MJ. Monoamine oxidase: from genes to behaviour. Annu. Rev. Neurosci. 22, 197-217 (1999).
135. Fan M, Liu B, Jiang X, Zhao H, Zhang J. Meta-analysis of the associations between the monoamine oxidase-A gene and mood disorders. Psychiatr. Genet. 20, 1-7 (2010).
136. Wild GC, Benzel EC. Essentials of Neurochemistry (Chapter 7) . Jones and Bartlett Publishers, MA, USA (1994).
137. Verbeek E, Bevova M, Hoogendijk W, Heutink P. The genetics of MDD - a review of challenges and opportunities. J. Depress. Anxiety 3, 2 (2014).
138. Sullivan PF, de Geus EJ, Willemsen G et al. Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Mol. Psychiatry 14, 359-375 (2009).
139. Verhagen M, van der Meij A, van Deurzen P et al. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity meta-analysis BDNF and MDD; gender and ethnicity. Mol. Psychiatry 15, 260-271 (2010).
140. Tammiste A, Jiang T, Fischer K et al. Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression. J. Psychopharmacol. 27(10), 915-920 (2013).
141. Caspi A, Sugden K, Moffitt TE. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301, 386-389 (2003).
142. Holden C. Depression gene. Back to the drawing board for psychiatric genetics. Science 324, 1628 (2009).
143. Blalock JE. Shared ligands and receptors as molecular mechanism for communication between the immune and neuroendocrine system. Ann. NY Acad. Sci. 741, 292-298 (1994).
144. Sternberg EM. Neural-immune interaction in health and disease. J. Clin. Invest. 100, 2641-2647 (1997).
145. Muller N, Ackenheil M. Psychoneuronimmunology and cytokine action in the CNS: implications for psychiatric disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 19, 65-74 (1998).
146. Sullivan PF, Fan C, Perou CM. Evaluating the comparability of gene expression in blood and brain. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B, 261-268 (2006).
147. Iga J, Euno S, Yamauchi K, Numata S, Tayoshi-Shibuya S, Kinouchi S. Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Biol. Psychiatry 31, 658-663 (2007).
148. Otsuki K, Uchida S, Watanuki T et al. Altered expression of neurotrophic factors in patients with major depression. J. Psychiatr. Res. 42, 1145-1153 (2008).
149. Lesch KP, Aulakh CS, Wolozin BL, Tolliver TJ, Hill JL, Murphy DL. Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Brain Res. Mol. Brain Res. 17, 31-35 (1993).
150. Mehta D, Menke A, Binder EB. Gene expression studies in major depression. Curr. Psychiatry Rep. 12, 135-144 (2010).
151. Spijker S, Van Zanten JS, De Jong S et al. Stimulated gene expression profiles as a blood marker of major depressive disorder. Biol. Psychiatry 68, 179-186 (2010).
152. Sibille E, Wang Y, Joeyen-Waldorf J et al. A molecular signature of depression in the amygdala. Am. J. Psychiatry 166, 1011-1024 (2009).
153. Lalovic A, Klempan T, Sequeira A, Luheshi G, Turecki G. Altered expression of lipid metabolism and immune response genes in the frontal cortex of suicide completers. J. Affect. Disord. 120, 24-31 (2010).
154. Kang HJ, Adams DH, Simen A et al. Gene expression profiling in postmortem prefrontal cortex of major depressive disorder. J. Neurosci. 27(48), 13329-13340 (2007).
155. Choudary PV, Molnar M, Evans SJ et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc. Natl Acad. Sci. USA 102, 15653-15658 (2005).
156. Aston C, Jiang L, Sokolov BP. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol. Psychiatry 10, 309-322 (2005).
157. Kozics T, Tilburg-Ouwens D, Faludi G, Palkovits M, Roubos E. Gender-related urocortin 1 and brain-derived neurotrophic factor expression in the adult human midbrain of suicide victims with major depression. Neuroscience 152, 1015-1023 (2008).
158. Sequeira A, Mamdani F, Ernst C et al. Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS ONE 4, e6585 (2009).
159. Holliday R. DNA methylation and epigenetic mechanisms. Cell Biophys. 15, 15-20 (1989).
160. Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science 286, 481-486 (1999).
161. Abdolmaleky HM, Smith CL, Faraone SV et al. Methylomics in psychiatry: modulation of gene-environment interactions may be through DNA methylation. Am. J. Med. Genet. B Neuropsychiatr. Genet. 127B, 51-59 (2004).
162. Liu L, Li Y, Tollefsbol TO. Gene-environment interactions and epigenetic basis of human diseases. Curr. Issues Mol. Biol. 10, 25-36 (2008).
163. Poulsen P, Esteller M, Vaag A, Fraga MF. The epigenetic basis of twin discordance in age-related diseases. Pediatr. Res. 61, 38R-42R (2007).
164. Lam LL, Emberly E, Fraser HB et al. Factors underlying variable DNA methylation in a human community cohort. Proc. Natl Acad. Sci. USA 109, 17253-17260 (2012).
165. Toyokawa S, Uddin M, Koenen KC, Galea S. How does the social environment 'get into the mind'? Epigenetics at the intersection of social and psychiatric epidemiology. Soc. Sci. Med. 74, 67-74 (2012).
166. Schroeder M, Krebs MO, Frieling H. Epigenetics and depression: current challenges and new therapeutic options. Curr. Opin. Psychiatry 23(6), 588-592 (2010).
167. Weaver IC, Cervoni N, Champagne FA et al. Epigenetic programming by maternal behavior. Nat. Neurosci. 7(8), 847-854 (2004).
168. Kruman II, Culmsee C, Chan SL et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J. Neurosci. 20, 6920-6926 (2000).
169. Kruman II, Kumaravel TS, Lohani A et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J. Neurosci. 22, 1752-1762 (2002).
170. Celada P, Perez J, Alvarez E, Artigas F. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement. J. Clin. Psychopharmacol. 12(5), 309-315 (1992).
171. Engstrom G, Alsen M, Regnell G, Traskman-Bendz L. Serum lipids in suicide attempters. Suicide Life Threat. Behav. 25(3), 393-400 (1995).
172. Markianos M, Alevizos B, Hatzimanolis J, Stefanis C. Effects of monoamine oxidase A inhibition on plasma biogenic amine metabolites in depressed patients. Psychiatr. Res. 52(3), 259-264 (1994).
173. Merali Z, Du L, Hrdina P. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J. Neurosci. 24, 1478-1485 (2004).
174. Burke HM, Davis MC, Otte C, Mohr DC. Depression and cortisol responses to psychological stress: a meta-analysis. Psychneuroendocrinology 30, 846-856 (2005).
175. Steen NE, Methlie P, Lorentzen S et al. Altered systemic cortisol metabolism in bipolar disorder and schizophrenia spectrum disorders. J. Psychiatr. Res. 52, 57-62 (2014).
176. Pace TW, Heim CM. A short review on the psychoneuroimmunology of posttraumatic stress disorder: from risk factors to medical comorbidities. Brain Behav. Immun. 25(1), 6-13 (2011).
177. Irwin M. Immune correlates of depression. In: Cytokines, Stress and Depression . Dantzer R, Wollman EE, Yirmiya R (Eds). Kluwer Academic/Plenum Publishers, NY, USA, 1-24 (1999).
178. Nunes, SOV, Reiche, EMV, Morimoto HK et al. Immune and hormonal activity in adults suffering from depression. Braz. J. Med. Biol. Res. 35, 581-587 (2002).
179. Naudé PJ, Eisel UL, Comijs HC et al. Neutrophil gelatinase-associated lipocalin: a novel inflammatory marker associated with late-life depression. J. Psychosom. Res. 75(5), 444-450 (2013).
180. Raison CL, Miller AH. Do cytokines really sing the blues. Cerebrum 2013, 10 (2013).
181. Becking K, Boschloo L, Vogelzangs N et al. The association between immune activation and manic symptoms in patients with a depressive disorder. Transl. Psychiatry 3, e314 (2013).
182. Karlovic D, Serretti A, Jevtovic S, Vrkic N, Seric V, Peles AM. Diagnostic accuracy of serum brain derived neurotrophic factor concentration in antidepressant naive patients with first major depression episode. J. Psychiatr. Res. 47(2), 162-167 (2013).
183. Lee BH, Kim YK. Increased plasma VEGF levels in major depressive or manic episodes in patients with mood disorders. J. Affect. Disord. 136(1-2), 181-184 (2012).
184. Kahl KG, Bens S, Ziegler K et al. Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology 34(3), 353-357 (2009).
185. Takebayashi M, Hashimoto R, Hisaoka K, Tsuchioka M, Kunugi H. Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders. J. Neural Transm. 117(9), 1119-1122 (2010).
186. Zhang X, Zhang Z, Xie C et al. Effect of treatment on serum glial cell line-derived neurotrophic factor in depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(3), 886-890 (2008).
187. Tseng PT, Lee Y, Lin PY. Age-associated decrease in serum glial cell line-derived neurotrophic factor levels in patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 40, 334-339 (2013).
188. Halmai Z, Dome P, Dobos J et al. Peripheral vascular endothelial growth factor level is associated with antidepressant treatment response: results of a preliminary study. J. Affect. Disord. 144(3), 269-273 (2013).
189. Minelli A, Zanardini R, Abate M, Bortolomasi M, Gennarelli M, Bocchio-Chiavetto L. Vascular endothelial growth factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(5), 1322-1325 (2011).
190. Carlino D, De Vanna M, Tongiorgi E. Is altered BDNF biosynthesis a general feature in patients with cognitive dysfunctions? Neuroscientist 19(4), 345-353 (2013).
191. Huang L, Jia J, Liu R. Decreased serum levels of the angiogenic factors VEGF and TGF-beta1 in Alzheimer's disease and amnestic mild cognitive impairment. Neurosci. Lett. 550, 60-63 (2013).
192. Ventriglia M, Zanardini R, Bonomini C et al. Serum brain-derived neurotrophic factor levels in different neurological diseases. Biomed. Res. Int. 2013, 901082 (2013).
193. Hashimoto K, Shimizu E, Komatsu N et al. Increased levels of serum basic fibroblast growth factor in schizophrenia. Psychiatr. Res. 120(3), 211-218 (2003).
194. Straten G, Eschweiler GW, Maetzler W, Laske C, Leyhe T. Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer's disease and normal controls. J. Alzheimers Dis. 18(2), 331-337 (2009).
195. Lo LH, Huang TL, Shiea J. Acid hydrolysis followed by matrix-assisted laser desorption/ionization mass spectrometry for the rapid diagnosis of serum protein biomarkers in patients with major depression. Rapid Commun. Mass Spectrom. 23(5), 589-598 (2009).
196. Huang TL, Cho YT, Su H, Shiea J. Principle component analysis combined with matrix-assisted laser desorption ionization mass spectrometry for rapid diagnosing the sera of patients with major depression. Clin. Chim. Acta 424, 175-181 (2013).
197. Domenici E, Wille DR, Tozzi F et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS ONE 5(2), e9166 (2010).
198. Arnold SE, Xie SX, Leung YY et al. Plasma biomarkers of depressive symptoms in older adults. Transl. Psychiatry 2, e65 (2012).
199. Johnston-Wilson NL, Sims CD, Hofmann JP et al. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol. Pharmacol. 5, 142-149 (2000).
200. Martins-de-Souza D, Guest PC, Harris LW et al. Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Transl. Psychiatry 2, e87 (2012).
201. Martins-de-Souza D, Guest PC, Vanattou-Saifoudine N, Rahmoune H, Bahn S. Phosphoproteomic differences in major depressive disorder postmortem brains indicate effects on synaptic function. Eur. Arch. Psychiatry Clin. Neurosci. 262, 657-666 (2012).
202. Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders. Proteomics 6, 3414-3425 (2006).
203. Yang Y, Yang D, Tang G et al. Proteomics reveals energy and glutathione metabolic dysregulation in the prefrontal cortex of a rat model of depression. Neuroscience 247, 191-200 (2013).
204. Piubelli C, Carboni L, Becchi S, Mathé AA, Domenici E. Regulation of cytoskeleton machinery, neurogenesis and energy metabolism pathways in a rat gene-environment model of depression revealed by proteomic analysis. Neuroscience 176, 349-380 (2011).
205. Hu Y, Zhou J, Fang L et al. Hippocampal synaptic dysregulation of exo/endocytosis-associated proteins induced in a chronic mild-stressed rat model. Neuroscience 230, 1-12 (2013).
206. Ghosh D, Poisson LM. "Omics" data and levels of evidence for biomarker discovery. Genomics 93, 13-16 (2009).
207. Fehrmann RS, de Jonge HJ, Ter Elst A et al. A new perspective on transcriptional system regulation (TSR): towards TSR profiling. PLoS ONE 3, e1656 (2008).
208. Azuaje F, Devaux Y, Wagner D. Computational biology for cardiovascular biomarker discovery. Brief Bioinform. 10, 367-377 (2009).
209. Schwarz E, Guest PC, Steiner J, Bogerts B, Bahn S. Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients. Transl. Psychiatry 2, e82 (2012).
210. Nouretdinov I, Costafreda SG, Gammerman A et al. Machine learning classification with confidence: application of transductive conformal predictors to MRI-based diagnostic and prognostic markers in depression. Neuroimage 56, 809-813 (2011).
211. Abu-Asab MS, Chaouchi M, Alesci S et al. Biomarkers in the age of omics: time for a systems biology approach. Omics 15, 105-112 (2011).
212. Kotaleski JH, Blackwell KT. Modelling the molecular mechanisms of synaptic plasticity using systems biology approaches. Nat. Rev. Neurosci. 11, 239-251 (2010).
213. Kubera M, Curzytek K, Duda W et al. A new animal model of (chronic) depression induced by repeated and intermittent lipopolysaccharide administration for 4 months. Brain Behav. Immun. 31, 96-104 (2013).
214. Neumann ID, Wegener G, Homberg JR et al. Animal models of depression and anxiety: What do they tell us about human condition? Prog. Neuropsychopharmacol. Biol. Psychiatry 35(6), 1357-1375 (2011).
215. Hoyer D, Waeber C, Pazos A, Probst A, Palacios JM. Identification of a 5-HT1 recognition site in human brain membranes different from 5-HT1A, 5-HT1B and 5-HT1C sites. Neursci. Lett. 85, 357-362 (1988).
216. Adham N, Romanienko P, Hartig P, Weinshank RL, Branchek T. The rat 5-hydroxytryptamine 1B receptor is the species homologue of the human 5-hydroxytryptamine 1D beta receptor. Mol. Pharmacol. 41, 1-7 (1992).
217. Cremers TI, Spoelstra EN, de Boer P et al. Desensitisation of 5-HT autoreceptors upon pharmacokinetically monitored chronic treatment with citalopram. Eur. J. Pharmacol. 397, 351-357 (2000).
218. Krishnan V, Nestler EJ. Animal models of depression: molecular perspectives. Curr. Top. Behav. Neurosci. 7, 121-147 (2011).
219. Domenici E, Muglia P. The search for peripheral disease markers in psychiatry by genomic and proteomic approaches. Expert Opin. Med. Diagn. 1(2), 235-251 (2007).
220. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 68, 89-95 (2001).